Held by
0
portfolios on TandT
Bookmarked by
0
users
Avg position size
—
of holders' portfolios
13F filers
0
institutions
52-week range
$10.45 – $16.34
15% from low
Exchange
OTC Link
ADRC
Borrow rate
28.96%
Hard to borrow
Click rows below (any statement) to add/remove series. Selection stays as you switch tabs.
| 2018 | 2019 | 2020 | 2021 | 2022 | 2023 | 2024 | 2025 | |
|---|---|---|---|---|---|---|---|---|
| Revenue | $1.83B | $1.83B | $1.89B | $2.04B | $2.07B | $2.14B | $2.29B | $2.44B |
| Cost of revenue | $858.3M | $871.6M | $875.5M | $915.2M | $968.6M | $941.8M | $1.01B | $1.10B |
| Gross profit | $973.8M | $955.6M | $1.02B | $1.12B | $1.12B | $1.20B | $1.28B | $1.35B |
| Gross margin | 53.2% | 52.3% | 53.8% | 55.1% | 53.9% | 56.0% | 56.1% | 55.2% |
| R&D | $49.9M | $53.8M | $82.4M | $94.5M | $92.0M | $110.4M | $111.7M | $113.3M |
| Operating income | $267.7M | $96.9M | $211.0M | $203.6M | $207.3M | $262.7M | $324.9M | $408.0M |
| EBITDA | $461.5M | $292.4M | $390.7M | $398.1M | $454.3M | $455.5M | $540.2M | $632.5M |
| Net income | $221.6M | $9.8M | $112.5M | $117.6M | $62.9M | $130.3M | $190.5M | $175.4M |
| Net margin | 12.1% | 0.5% | 5.9% | 5.8% | 3.0% | 6.1% | 8.3% | 7.2% |
| EPS (diluted) | 0.45 | 0.02 | 0.22 | 0.23 | 0.12 | 0.25 | 0.37 | 0.34 |
Annual figures · source: Financial Modeling Prep
| Year | Est. revenue | Est. EPS | EPS range | # Analysts |
|---|---|---|---|---|
| 2026 | $2.6B | $0.79 | $0.77–$0.80 | 1 |
| 2027 | $2.7B | $0.90 | $0.88–$0.92 | 1 |
| 2028 | $2.9B | $1.01 | $0.98–$1.02 | 1 |
| 2029 | $3.1B | $1.11 | $1.08–$1.13 | 1 |
Forward consensus · source: Financial Modeling Prep
CONVATEC GRP PLC UNSP/ADR
No one on the platform currently holds CNVVY.
No tracked institution reports a position in CNVVY as of their last filing.
| Ex-date | Per share | Pay date |
|---|---|---|
| 2026-04-17 | $0.2134 | 2026-06-11 |
| 2025-08-22 | $0.0756 | 2025-10-16 |
| 2025-04-22 | $0.1957 | 2025-06-12 |
| 2024-08-23 | $0.0745 | 2024-10-21 |
| 2024-04-25 | $0.1790 | 2024-06-07 |
| 2023-08-17 | $0.0672 | 2023-10-13 |
No one on the platform has traded CNVVY yet.
| $5.6B |
| — |
| RADLYRaia Drogasil S.A. | $3.44 | +3.93% | $6.0B | — |
| SHPMYShanghai Pharmaceuticals Holding Co., Ltd | $7.34 | +0.00% | $5.4B | — |
Source: Financial Modeling Prep · peers by sector/industry
No recent Form 4 filings on EDGAR — either no insider transactions reported recently or this isn't a SEC-registered issuer.
Trading at 30.3× earnings vs its 41.6× historical median P/E.
Fair value ≈ $15.61 · price $11.36 today
Fair-value line = the stock's median historical P/E × earnings. Price below the orange line = cheap vs its own history; above = expensive. Not investment advice.